Smith & Nephew (NYSE:SNN) said today that CEO Olivier Bohuon plans to remain “actively involved” in running the British healthcare giant during his treatment for a “highly treatable” type of cancer.
The treatment, to include chemotherapy, is slated to begin later this month, Smith & Nephew said.
Chairman Roberto Quarto will provide executive oversight if necessary as part of its provisional governance procedures, the company said.
“Olivier has set a clear strategy that is invigorating Smith & Nephew’s growth profile. I am confident that Olivier and his team will continue to execute the plan successfully. Our thoughts are with him as he undergoes treatment,” Quarta said in prepared remarks.
Bohuon is still slated to present Smith & Nephew’s 4th-quarter and 2015 results Feb. 4, the company said.
Last year, Cardiovascular Systems (NSDQ:CSII) revealed that CEO David Martin was also diagnosed with cancer. Martin took a 3-month leave beginning Dec. 31 to undergo further treatment, including chemotherapy. Prism Medical (TSX:PM) chairman & CEO Andrew McIntyre took a 6-month leave of absence for chemotherapy following his diagnosis of non-Hodgkin lymphoma late last year, with vice chairman John Charles named interim CEO.
The post Smith & Nephew CEO to stay on during cancer treatment appeared first on MassDevice.
from MassDevice http://ift.tt/202g4xr
Cap comentari:
Publica un comentari a l'entrada